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ABSTRACT 
Objective: AF9-MLL has been implicated in the pathogenesis of AML, New Therapeutic regimens are prerequisite for this category of hematological 
malignancy due to the poor prognosis. The experimental 3D structure of AF9-MLL is not available. Therefore, present study aims in developing the 
homology model and evaluating the best model through Energy Minimization and MD simulation. The structure further analyzed for functional 
Annotation.  
Methods: To the best of our knowledge, our study is novel in terms of predicting homology based 3D model of AF9-MLL leukemogenic fusion 
protein, facilitated by I-TASSER. The 3D modeled structure was subsequently optimized with MD simulation for 2 ns. Further stereo-chemical 
analysis and verification of the best structure so obtained were undertaken by different computational programs including PROCHECK, PROVE, 
Verify3D and ERRAT.  
Results: Homology model predicted from I-TASSER and refined by YASARA showed results with 86.5% residues in the most favorable region, 
14.7% in the allowed region, 0.8% in the generously allowed region and 0.3% in the disallowed region. The RMSD between the modeled and the 
refined structure was found to be 2.37 Å. The results of ERRAT, Verify_3D, Prove and ProSA confirmed that the simulated model and energy 
minimized model is very good then the predicted raw model. The final structure was successfully submitted in Protein Model Database (PMDB) 
under ID: PM0080061. 
Conclusion: In this study, homology model was developed and Validated for MLL-AF9 using bio-informatics tools. These analyses validated that the 
simulated model is best, robust as well as reliable enough to be used for future study and the functional analysis shows the presence of CXXC 
domain. Eventually, these molecular and structural studies result in advancement of newer therapies. 
Keywords: MLL, Fusion Protein, Molecular modeling, Simulation, Structure Prediction. 
 
INTRODUCTION 
Chromosomal anomalies are regarded as one of the major hallmark 
of neoplastic cells, and the continual occurrence of chromosomal 
instability has been manifested in human neoplasia. Amongst these, 
recurrent reciprocal chromosomal translocations between non-
homologous chromosomes are exclusively found to be implicated in 
the etiology of numerous hematological malignancies [1]. Balanced 
chromosomal rearrangements are crucial cellular mechanism, which 
lead to malignant transformation of normal cell via formation of 
chimeric fusion protein. 5–6% cases of Acute Myeloid Leukemia 
(AML) and 5–10% of acute lymphoblastic leukemia’s (ALLs) cases 
are observed with the presence of chromosomal translocations 
involving the long arm (q23) of chromosome 11 [2]. Remarkably, the 
occurrence of 11q23 rearrangements is appreciably higher in 
pediatric AML and infant ALL. The Mixed-Lineage Leukemia (MLL) 
gene encodes the complex transcription factor that leads to the 
formation of unique hybrid genes, whose protein products are 
believed as critical elements in initiation of leukemogenesis. This 
multi exonic segment contains cluster of translocation breakpoints 
around exon 8 and various translocations partner genes combine 
with MLL gene yielding specific fusion protein responsible for 
development of a specific subtype of leukemia [3-8].  
Till date, there have been more than 50 fusion gene partners 
reported for MLL. Amongst all MLL translocations, around 50% of 
infant AML cases comprises of t(9,11)(p22,q23) rearrangement. AF9 
gene also known as LTG9 or MLLT3 is located at short arm p22 of 
chromosome 9 [9-11]. From several experimental studies, it was 
evident that leukemogenesis is caused by formation of MLL-AF9 
fusion protein but still the mechanism of these partner genes is 
anonymous. In contrast, few other in-vitro and in-vivo analysis 
revealed that MLL-AF9 alters myeloid progenitor cells and 
suppresses specific HOX gene e. g. mice with knock-in AF9-MLL 
fusion gene demonstrated anomalous proliferation of hematopoietic 
cell and developed AML identical to patient with t (9; 11) 
translocation [12-14]. Also, MLL and AF9 wild protein forms 
participate indispensably during hematopoiesis/embryogenesis 
process and are elements of protein complexes resulting in target 
gene transcriptional initiation (MLL) and elongation (AF9). 
Therefore it is hypothesized that MLL-AF9 fusion combines these 
characteristics, resulting in increased activation of target genes 
which may be interrupt hematopoietic cell differentiation and 
ultimately leads to leukemogenesis [15-19]. As the occurrence of 
11q23 translocations is associated with extremely poor prognosis, 
novel therapeutic strategies are needed to be explored for this 
category of hematological malignancy. In spite of tremendous 
interest concerned with designing of target specific drug like 
molecules against this fusion protein. However, blocked by the 
unavailability of pertinent structural data. Additionally, structural & 
functional analysis of this chimeric gene (AF9-MLL) is required to be 
profoundly studied to get better insight into the causal mechanism 
leading to leukemogenesis. To resolve these problems, development 
of three dimensional molecular structure of AF9-MLL fusion protein 
is of prime importance with aim to discover newer alternative drug 
like compounds that precisely targets MLL-AF9 positive AML.  
The fig. 1 shows the reciprocal chromosomal translocation between 
chromosome 9 and 11. Due to these translocation two genes fused 
and codes for oncogenic Fusion protein. To the best of our 
knowledge, our study is novel in terms of predicting the homology 
based 3D model of AF9-MLL leukemogenic fusion protein, 
undertaken by I-TASSER. The 3D model structure was subsequently 
optimized with MD simulation and further stereo-chemical 
validation studies and functional analysis of the best structure so 
obtained were executed by means of different computational 
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programs including PROCHECK, PROVE, Verify3D, ERRAT, NCBI-
CDD, Pro Know and Inter Pro Scan.  
MATERIALS AND METHODS 
Sequence retrieval 
The amino acid sequence of AF9-MLL fusion protein was retrieved 
from Uni Prot Database (http://www. uniprot. org/) submitted 
under the name of HUMAN putative AF9-MLL fusion protein with 
sequence ID of Q6TU33 and Entry name of Q6TU33_HUMAN having 
total sequence length 107 amino acid residues [20]. This sequence 
so retrieved in FASTA format was utilized for further structural 
characterization and functional analysis. 
Protein structure prediction 
Full length AF9-MLL fusion protein sequence was uploaded to the I-
TASSER (Iterative Threading Assembly Refinement) server 
(http://zhanglab. ccmb. med. umich. edu/I-TASSER) for three 
dimensional structure predictions with default parameters. I-TASSER 
utilizes total four step protocol to unite alignment based model of 
existing protein structure with ab-initio model of unaligned regions in 
query protein to eventually provide alternatives of best scoring protein 
models [21]. The protein model was built from multiple sequence 
alignment of the query protein sequence with the template sequence 
with known structure and function [22]. The modeled structures were 
chosen on the base of sequence similarity with the Protein Data Bank 
(PDB) templates and the energy minimization step was performed using 
YAMBER force field of YASARA plugin server [23]. 
Refinement of modeled structure 
The preliminary 3D model of AF9-MLL fusion protein acquired from 
homology modeling was further refined by Molecular Dynamic (MD) 
simulation in order to improve the accuracy of the structure. Here, 
MD simulation was accomplished by YASARA plugin which utilizes 
the molecular dynamics macro called md_refine for enhancement of 
built model which consequently lessens the steric hindrances 
amongst the residues and thereby contributes towards overall 
stabilization of protein backbone. During simulation, model was 
solvated with water molecules and Conjugate Gradient protocol 
subsequent to steepest descent algorithm was undertaken in order 
to perform initial energy minimization steps.  
Ultimately, the global minimization of model was attained by 
Simulated Annealing for eradication of redundant contact area 
among protein atoms & water molecules. Briefly, the predicted 
structure was then simulated inside trajectory box filled with 0.9% 
of NaCl ions (physiological condition) and water molecules by 
YASARA2 force-field using default parameter of macro and the NVT 
canonical ensemble. The pH was 7.4, temperature was 298ο
 
K and 
the density was 0.997 throughout the refinement. The data of 
protein model produced using YASARA got after simulation was 
investigated for trajectory projection [24]. 
 
Fig. 1: Reciprocal translocation between chromosome 9 and 11 leads to AF9-MLL fusion gene codes for Novel Fusion Protein. Structure 
prediction of fusion protein through Homology Modeling 
 
Validation of modeled structure 
The predicted Models were further considered for accurate 
validation and verification by PROCHECK server [25] (http://www. 
ebi. ac. uk/thornton-srv/software/PROCHECK/) for stereo-chemical 
analysis of dihedral angles in modeled protein structure. PROCHECK 
analyzes overall residue by residue/structural geometry as 
determine by Ramachandran plot. VERIFY 3D (http://services.mbi. 
ucla.edu/Verify_3D/) [26] decides similarity of model with its own 
amino acid sequence (1-D) by allocating structural class based on its 
location and environment, thus comparing results of superior 
structures. ERRAT (http://nihserver. mbi. ucla. edu/ERRAT/) [27] is 
a protein structure verification algorithm for assessing progression 
of crystallographic model building and refinement. The program 
scrutinizes the statistics of non-bonded interaction between 
different atom types which is useful to check structural reliability. 
PROVE (Protein Volume Evaluation) calculates the volume of atoms 
in macromolecules [28].  
Functional analysis of predicted structure 
The domain analysis was performed to obtain accurate function of 
predict protein. The function domain of protein was predicted by 
means of different publicly accessible protein family databases. NCBI 
Conserved Domains Database (NCBI-CDD) which is a collection of 
sequence alignments and profiles representing protein domains 
conserved in molecular evolution. It also includes alignments of the 
domains to known 3-dimensional protein structures in the MMDB 
database [29]. Pro Know server and Inter-Pro Scan also predict the 
function of proteins from the given structure, are also utilized for 
functional annotation of this fusion protein [30, 31].  
RESULTS AND DISCUSSION 
The eventual objective of computational protein modeling is to 
anticipate a protein structure from its amino acid sequence with a 
precision that is analogous to the finest outcome accomplished by 
various sophisticated experimental techniques. This would permit 
use of in silico predicted structures in all the perspective where 
currently just experimental structures offer a concrete base for 
protein function annotation, structure based drug designing, 
interactions analysis and antigenicity, and rational designing of 
proteins with improved steadiness or unique functionality. 
Moreover, protein modeling is the only approach to gain structural 
information in case of failure faced during experimental 
methodologies and sometimes few proteins are too hefty for X-ray 
diffraction and NMR analysis. Amongst the three main methods of 
3D structure prediction, homology modeling is comparatively 
reliable and easier than other approaches [32-34]. The current study 
centered on structural and functional analysis of AF9-MLL oncogenic 
fusion protein.  
Three dimensional model building 
Various online tools/server are accessible for homology modeling of 
proteins and previous studies established that a sequence similarity 
higher than 25% among two proteins is significative of analogous 3D-
structures [35]. Here, in order to execute homology modeling, the 
amino acid sequence in the query was subjected as input to I-TASSER 
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server. This server employs the method where the sequence of target 
is threaded by utilizing an emblematic PDB structure library to explore 
for the probable folds through numerous prominent alignment 
algorithms including Needleman-Wunch & Smith-Waterman, PSI-
BLAST, Hidden Markov Model (HMM) and Profile-Profile Alignment 
(PPA). The server robotically carries out BLASTP for every protein 
sequence to recognize best possible templates for homology modeling 
and in total ten best alignments was incurred through implementation 
of versatile threading programs (Neff-PPAS, MUSTER, SPARKS-X, 
FAS03, SP3, PROSPECT2 etc) (table 1). For every recognized template, 
the template's lineament has been anticipated from characteristics of 
target-template alignment. After extensive sequence & structure 
alignments, the templates with the utmost value have then been 
preferred for constructing the molecular model [21]. In this case, PDB 
ID 2YSM had the most excellent Z-score of 4.96 obtained from all the 
algorithms and was chosen as the template for homology modeling 
which is the solution structure of the first & second PHD domain from 
Myeloid/lymphoid or mixed-lineage leukemia protein 3 homolog. I-
TASSER anticipated 5 models in total, from which the model with best 
Conf-Score of 0.32 was selected with estimated accuracy of 0.76 (TM-
Score) and 3.5 Å (RMSD). The 3D protein structure so modeled was 
visualized by Pymol. 
 
Table 1: Top identified structural analogs in PDB used by I-Tasser to model the protein 
Rank PDB Hit TM-score RMSD A Identity ο coverange 
1 2ysmA 0.843 1.64 0.287 0.944 
2 2kwjA 0.719 2.67 0.267 0.944 
3 2ln0A 0.705 2.76 0.238 0.944 
4 4b9yA 0.504 4.09 0.067 0.878 
5 2x2hA 0.491 4.21 0.049 0.888 
6 2e6sA 0.485 2.98 0.264 0.635 
7 1llqB 0.474 4.66 0.049 0.906 
8 2aw5B 0.469 4.30 0.021 0.860 
9 2e6rA 0.467 2.04 0.333 0.551 
10 2k17A 0.462 3.01 0.185 0.589 
 
The modeled protein structure was undertaken for energy 
minimization by utilizing YASARA plugin [24]. Energy 
minimization is fundamentally in relation to "reconcile" the 
model into a reasonably energetically favorable condition. 
Protein structures (either NMR, modeled, crystallography or 
molecularly docked) frequently have fault of varied level and 
energy minimization seem to provide the most diminution in 
system’s energy on the whole by attenuating, non-bonded 
interactions, bond angles, lengths etc. into favorable condition to 
a greater extent. Energy minimization was executed by AMBER 
force field implemented in YASARA server to obtain optimized 
model structure with 6989.3 kJ/mol of initial energy to a final 
energy of − 2366.6 kJ/mol. The energy minimized model of AF9-
MLL fusion protein was considered for structural validation 
studies by various online tools and softwares like PROCHECK, 
VERIFY 3D, ERRAT and PROVE. 
  
 
Fig. 2: (a) Ramachandran plot values showing number of residues in favored, allowed and outlier region. (b) Errat plot where Black bars 
show the misfolded region, gray bars demonstrate the error region between 95% and 99%, and white bars indicate the region having less 
error rate for protein folding. (c) PROVE shows Z-score (c) PROVE Analysis of residues 
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Homology models are erroneous as structure emerges by a course of 
amino acid insertions, substitution and deletions [36-38]. 
Imprecision in model comprises of deformation in secondary 
structure elements, side chain packaging error and inadequately 
delineated loop conformations which necessitates that all predicted 
structures are mandatory for further refinement. Model 
enhancement is basically two step procedure where first, the local 
structural error are identified & eliminated through energy 
minimization and second, global (backbone) structural amendment 
for improving overall folds through MD simulation which is 
proficient sampling system to exactly recognize nearest native 
conformation [39-43]. Herein, extent of refinement was measured in 
terms of root mean square deviation (RMSD), by deviation of the 
resultant best fit structure against the initial structure in the course 
of simulation as a function of time. RMSD was calculated for the 
backbone and residues to verify the constancy of the trajectories. 
Moreover, the root mean square fluctuation (RMSF) was evaluated 
for each amino acid to analyze the flexibility of the trajectories. The 
predicted model fusion protein attained state of stabilization after 
1.7 ns and average RMSD all atoms and backbone congregated to 
1.63 Å (fig. 3e). The RMSF of individual residues is shown (fig. 3f) 
where the residues Asn 10 & 85, Ser 15, Gln 21 & 62 and Lys 101-Ser 
107 demonstrated elevated peaks suggesting higher fluctuation of 
those amino acids. Amongst these, Gln 21 and end chain fusion 
protein residues showing higher flexibility possess cysteine residue 
in their neighbourhood indicative of certainty that there is 
maximum destabilization found around CXXC Domain of AF9-MLL 
fusion protein which hence can be directly correlated with 
confrontational activation demonstrated by in-vitro studies [44, 45].  
Moreover, Leu 39 found in disallowed region of the Ramachandran 
plot was also contributing towards overall destabilization of protein 
as seen from trajectory. Optimized model demonstrated presence of 
86.5% of residues in favored zone which is higher than (46.9%) that 
of the raw modeled structure, signifying better steadiness of the 
refined structure. On the contrary, lower quality factor/scores were 
obtained from ERRAT & Verify3D for refined model as compared to 
higher values that of raw model, which is may be because of the 





Fig. 3: Superimposed view of all three structures: (a) Predicted (Pink color) with energy minimized structure (Green color). (b) Refined 
Structure after simulation (Grey color) with Energy Minimized (Green color). (c) All Three structure final view. (d) RMSD Trajectory 
Graph. (e) RMSF trajectory of predicted protein structure for 2 nano second 
 
Model validation, Quality assessment, and visualization 
Each homology model integrates errors and the error counts for a 
given system primarily rely upon two standards. First, the 
proportion sequence similarity among the target & template and 
second is the total counts of erroneousness in template [46]. 
Consequently, authentication of the model is an indispensable step 
in the procedure of homology modeling. Validation studies were 
performed for model which includes analysis of geometric 
properties of backbone conformations by utilizing numerous 
structure evaluation tools and the results displayed in tabular form 
(table 2) verifies the superior model quality.  
The PROCHECK examination on basis of Ramachandran plot endows 
with an interpretation about the stereo-chemical characteristic of 
the protein model. It focuses on protein regions that seemed to 
possess atypical geometry and allows for structural assessment on 
the whole [25]. 
Rawal et al. 
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Table 2: Comparative values of Procheck, Errat, Verify_3D, Prove in different stages of refinement used in I-TASSER software 
Validation  Predicted model Model energy minimized Model_refined 
Procheck Regions of ramachandran plot    
 Favoured 46.9% 67.2% 86.5% 
 Additionally allowed 43.8% 27.1% 10.4% 
 Generously allowed 6.2% 2.1% 2.1% 
 Disallowed 3.1% 3.1% 1.0% 
ERRAT  86.869 95.918 77.273 
VERIFY_3D  82.24 90.65 72.90 
PROVE Z score  Error 0.767 0.541 
 
The Ramachandran plot in fig. 2a designated the area of probable 
angle formations by psi and phi angles. The traditional term 
correspond to the torsional angles on both side of α-carbon in 
peptides. Thus, statistical investigation through PROCHECK provides 
the legitimate statistical factor that 67.2% of protein residues 
appeared in favorable region, 29.2% of residues falls in an allowed 
region and 3.1% of residues i.e. only one residue (Leu39) is there in 
disallowed region, speculating some steric obstruction as a 
consequence of poor templates. For a superior models, the amino 
acids positioned in the favored and allowed regions is supposed to 
be greater than 90% which is holding true for the model existing 
here (that is, 67.2%+29.2% = 96.4%).  
This is suggestive of fact that the model so constructed is of the 
superior kind. The RMSD value of the predicted structure with 
energy minimized and refined structure is shown in table 3. 
 
Table 3: RMSD between modeled protein, Energy minized and simulated model of AF9-MLL fusion protein 
 Predicted model and energy 
minimized 
Energy minimized and simulated model Predicted model and simulated model 
RMSD[ A °] 0.56 2.29 2.37 
 
Consistency of the generated model was further computed by 
ERRAT which is a sophisticated methodology that calculates 
statistical organization of the particular kind of atom with respect to 
each other and is an exclusive approach for spotting erroneously 
folded regions in preliminary models. ERRAT hence gives overall 
quality factor for non-bonded interactions and the resultant higher 
score (with least accepted range of 50) is directly proportional to 
good model quality [27]. For the current model, overall estimated 
quality factor of ERRAT was 95.92 which is evocative of the fact that 
the structure is of good quality having high resolution with 
insignificant error standards of individual amino acid residues in 
modeled fusion protein (fig. 2b). The Verify 3D technique 
determines protein structures by means of three-dimensional 
visibilities. This tool evaluates the compatibility of 3D molecular 
model with its own (1D) amino acid sequence where the score 
ranges from-1 (not acceptable) to+1 (acceptable) [26]. As 
designates by the Verify3D server, the outcome demonstrated that 
90.65% of residues possessed mean 3D to1D score ≥ 0.2 which is 
symptomatically signifying that these structures were well-
matched and reasonably of high quality. Another model 
authentication tool, PROVE evaluates statistical Z-score deviation 
for the modeled protein by determining the volumes of atoms in 
macromolecules utilizing an algorithm which considers the atoms 
as solid spheres [28]. PROVE analysis demonstrated the average 
statistical Z-score value of 0.76 (fig. 2 c & d).  
From the entire results of structural validation program, it is 
deduced that the homology modeled protein is trustworthy for 
conducting further computational analysis on the oncogenic fusion 
protein including docking algorithms, molecular dynamic simulation 
in order to investigate protein–ligand interaction studies, moreover 
it aids in the recognition of potent ligands for particular therapeutic 
indications. 
Submission of the protein structure in protein model database 
(PMDB) 
The final authenticated modeled structure of AF9-MLL oncogenic 
fusion protein was successfully submitted in Protein Model 
Database (PMDB) after effectively surpassing PMDB stereo-chemical 
quality tests and it is accessible under PMDB ID: PM0080061. This 
insillico constructed proteins structures database is open for public 
use from where users can freely obtain the model by its accession 
number and these structures may be further utilized for 
experimental characterization of the protein. 
Functional annotation 
The predicted protein was analyzed for further functional 
annotation. Three web tools were used to search the conserved 
domains and potential function of AF9-MLL Fusion Protein. Based 
on consensus predictions made by NCBI-CDD, Pro Know and Inter 
Pro Scan it is confirmed that AF9-MLL belongs ADDZ superfamily 
and possesses PHD like Zinc finger Domain. NCBI-CDD recognizes 
(cl17040) ADDZ superfamily, e-value = 9.06e-04 with PHD Domain 
within residue range from 16-54 (fig. 4b) with Pfam database 
Accession Pfam 00628. NCBI-CDD further predicted that residues 
range from 54-102 the 42 amino acid have PHD repeating Zn 
binding sites which show Conserved feature residue pattern: C CCC 
H C C [HC] on [47] residue number 54,57,70,72,78,81,99 and 102 
(fig. 4a). The Inter Pro Scan could recognize that PHD-Type Zinc 
finger domain is present on the predicted model which is further 
confirmed by Pro Know Meta Server.  
The canonical PHD finger is identified as Tri-Thorax Consensus 
(TTC) domain or leukemia-associated protein (LAP) motif which is 
distinguished as Cys4HisCys3 and seemed to be present in wide 
range of proteins concerned with transcriptional regulation and 
chromatin dynamics. Especially, putting an emphasis on their 
spectacular regulatory potentials, these molecules can identify and 
interact with a huge repertory of proteins specifically including the 
modified/unmodified histone tail (H3) and non-histone proteins. In 
particular, they are specific molecular scaffolds that serve as reader 
of epigenome governing the genetic expression via molecular 
mobilization of numerous transcriptional molecules and chromatin 
regulatory factors constituting multi-protein complexes. The CXXC 
domain found in numerous chromatin-associated proteins is 
epitomized by two CGXCXXC repeats and it interacts with non-
methylated CpG di-nucleotides.  
Moreover, this domain encompasses eight conserved cysteine 
residues that bind to two zinc ions and its DNA binding interface has 
been recognized by NMR analysis. The RecQ helicase enzyme though 
possess single repeat that binds to zinc, is exception to be 
incorporated in family of this domain [48]. Results from PANTHER 
Family confirm that the GO molecular function shows activity of 
Methyltransferase and DNA binding activity of AF9-MLL protein. 
The function of this protein is to interact selectively and non-
covalently with Zinc (Zn) ions based on a KEGG search AF9-MLL 
fusion protein was not found to be essentially involved in any of the 
bio metabolic pathways till the date.  
Rawal et al. 




Fig. 4: Result obtained from NCBI conserved domain database. (a) Conserved feature residue pattern C CCC H CC[HC]:The Zn binding site. 
(b) PHD-type Zinc finger Domain of ADDz protein Family on predicted structure 
 
CONCLUSION 
This fusion protein was found to be critically associated with 
underlying leukemogenesis pathway and consequently would be a 
potential drug target in treatment of pediatric AML harboring 
t(9;11)(p22;q23). Lack of structural information till the date about this 
fusion protein obstructs the comprehensive characterization of its 
biological functions and its relevance in structure based design. For 
this reason, it was indispensable to develop the model of AF9-MLL 
fusion protein. The current study was conducted to construct the first 
3 dimensional structure & to suggest potential functions of the AF9-
MLL fusion protein. The model was created by homology modeling 
technique as well as optimized by MD simulation is near in-vitro 
environment. After refinement of the model, validation of structure 
was carried out with appropriate online tools. Outcome of these 
verification tools and low RMSD score signifies that the ultimate 
protein product was reasonably of superior quality. This modeled 
structure can be accessed at protein model database PMDB (ID: 
PM0080061). Additionally, better-quality modeled structure of AF9-
MLL oncogenic protein may be further utilized in molecular docking & 
simulation studies and drug discovery. 
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